Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...

...CR2-fH substantially reduced disease activity and joint damage... An inhibitor of the alternative pathway (AP) of complement activation reduces clinical disease activity and joint damage in an ...

RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated >99 percent ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 12% after the company announced the closing of its asset purchase and license agreement with Novo Nordisk for its clinical-stage MASP-3 ...

Omeros Corporation (NASDAQ:OMER) surged 12% on Monday after the company confirmed it has officially completed its asset ...

CLEVELAND, Jan. 31, 2022 /PRNewswire/ -- NovelMed Therapeutics announced today that its Investigational New Drug Application (IND) to initiate clinical trials of its NM8074 biologic has been cleared ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

- Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for ...